Compare Glenmark Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ALEMBIC LTD - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ALEMBIC LTD GLENMARK PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 9.7 56.8 17.2% View Chart
P/BV x 1.2 2.3 53.8% View Chart
Dividend Yield % 0.8 0.4 183.5%  

Financials

 GLENMARK PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ALEMBIC LTD
Mar-18
GLENMARK PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs71272 988.3%   
Low Rs48434 1,426.5%   
Sales per share (Unadj.) Rs349.64.7 7,438.0%  
Earnings per share (Unadj.) Rs32.86.1 537.1%  
Cash flow per share (Unadj.) Rs44.36.2 709.9%  
Dividends per share (Unadj.) Rs2.000.20 1,000.0%  
Dividend yield (eoy) %0.30.4 88.6%  
Book value per share (Unadj.) Rs198.640.7 488.5%  
Shares outstanding (eoy) m282.17267.03 105.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.711.3 15.2%   
Avg P/E ratio x18.28.7 210.1%  
P/CF ratio (eoy) x13.58.5 159.0%  
Price / Book Value ratio x3.01.3 231.0%  
Dividend payout %6.13.3 186.2%   
Avg Mkt Cap Rs m168,62514,139 1,192.6%   
No. of employees `00012.0NA-   
Total wages/salary Rs m20,561207 9,913.5%   
Avg. sales/employee Rs Th8,196.0NM-  
Avg. wages/employee Rs Th1,708.1NM-  
Avg. net profit/employee Rs Th768.5NM-  
INCOME DATA
Net Sales Rs m98,6551,255 7,859.7%  
Other income Rs m2,081370 562.2%   
Total revenues Rs m100,7361,625 6,197.6%   
Gross profit Rs m15,858111 14,273.7%  
Depreciation Rs m3,25938 8,622.0%   
Interest Rs m3,3462 196,817.6%   
Profit before tax Rs m11,335442 2,565.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,75624 15,684.3%   
Profit after tax Rs m9,2501,630 567.5%  
Gross profit margin %16.18.9 181.6%  
Effective tax rate %33.15.4 611.3%   
Net profit margin %9.4129.8 7.2%  
BALANCE SHEET DATA
Current assets Rs m66,9681,867 3,586.8%   
Current liabilities Rs m40,211591 6,801.6%   
Net working cap to sales %27.1101.6 26.7%  
Current ratio x1.73.2 52.7%  
Inventory Days Days8394 88.4%  
Debtors Days Days8174 110.4%  
Net fixed assets Rs m33,3221,791 1,860.6%   
Share capital Rs m282534 52.8%   
"Free" reserves Rs m55,77010,324 540.2%   
Net worth Rs m56,05210,858 516.2%   
Long term debt Rs m35,73841 86,741.5%   
Total assets Rs m132,88811,591 1,146.5%  
Interest coverage x4.4260.9 1.7%   
Debt to equity ratio x0.60 16,802.5%  
Sales to assets ratio x0.70.1 685.5%   
Return on assets %9.514.1 67.3%  
Return on equity %16.515.0 109.9%  
Return on capital %17.815.2 117.3%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m62,99819 324,734.0%   
Fx outflow Rs m22,859264 8,664.5%   
Net fx Rs m40,140-244 -16,422.5%   
CASH FLOW
From Operations Rs m13,242236 5,615.6%  
From Investments Rs m-6,990-224 3,120.5%  
From Financial Activity Rs m-7,387-27 27,772.2%  
Net Cashflow Rs m-2,971-15 20,073.0%  

Share Holding

Indian Promoters % 48.3 64.0 75.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.2 3,450.0%  
FIIs % 34.4 9.7 354.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 26.1 40.2%  
Shareholders   56,727 54,701 103.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

LUPIN Surges by 13%; BSE HEALTHCARE Index Up 3.4% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

LUPIN share price has surged by 13% and its current market price is Rs 798. The BSE HEALTHCARE is up by 3.4%. The top gainers in the BSE HEALTHCARE Index are LUPIN (up 12.7%) and DIVIS LABORATORIES (up 6.2%). The top losers are J.B.CHEMICALS (down 0.2%) and PROCTER & GAMBLE HEALTH (down 1.2%).

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS